RxDoctor Payments Data

Tyreasea Johnson Mason, NP

Psychiatric/Mental Health · Haddon Township, NJNPI 1003250101

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,650 of the $36,011 with a category attached, or 82.3%. AbbVie accounts for 64.7% of it on its own, with 6 other manufacturers making up the rest. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,011in general payments, 2019–2025

Across 77 payments — averaging $467.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$23K
  • Axsome Therapeutics, Inc.$12K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$209
  • Sunovion Pharmaceuticals Inc.$120
  • Idorsia Pharmaceuticals US Inc$104
  • Otsuka America Pharmaceutical, Inc.$74
  • plus $27 from 1 others

What the payments were for

  • Consulting fees$5,20114%
  • Speaking & faculty fees$29,65082%
  • Food & beverage$1,1333%
  • Education$270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,011 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$30,375
Medicare patients
40
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl39$85,844
RexultiBrexpiprazole32$74,049
Lurasidone Hcl16$16,369
Desvenlafaxine Succinate ErDesvenlafaxine Succinate28$3,356
Lisdexamfetamine Dimesylate11$2,899
Venlafaxine Hcl ErVenlafaxine Hcl26$2,066
Bupropion XlBupropion Hcl58$1,687
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine53$1,497
Duloxetine Hcl31$1,401
Gabapentin81$1,302
Alprazolam129$1,202
Oxcarbazepine20$1,101
Clonazepam170$1,041
Modafinil29$923
Quetiapine Fumarate40$915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$23,309$85,84439 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74$74,04932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Haddon Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →